Wall Street Analysts Are Bullish on Top Healthcare Picks
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Nuvalent (NUVL – Research Report), Carlsmed, Inc. (CARL – Research Report) and AbCellera Biologics (ABCL – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Nuvalent (NUVL)
Truist Financial analyst Gregory Renza maintained a Buy rating on Nuvalent today. The company’s shares closed last Tuesday at $99.75.
According to TipRanks.com, Renza is a 5-star analyst with an average return of
Nuvalent has an analyst consensus of Strong Buy, with a price target consensus of $140.33, representing a 42.6% upside. In a report released today, Raymond James also maintained a Buy rating on the stock with a $133.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Carlsmed, Inc. (CARL)
Truist Financial analyst Richard Newitter maintained a Buy rating on Carlsmed, Inc. today. The company’s shares closed last Tuesday at $14.41.
According to TipRanks.com, Newitter is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Carlsmed, Inc. with a $20.67 average price target, representing a 40.7% upside. In a report issued on January 9, Goldman Sachs also maintained a Buy rating on the stock with a $20.00 price target.
AbCellera Biologics (ABCL)
In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on AbCellera Biologics. The company’s shares closed last Tuesday at $4.26.
According to TipRanks.com, Devarakonda is a 5-star analyst with an average return of
AbCellera Biologics has an analyst consensus of Strong Buy, with a price target consensus of $6.67.
